Insmed Incorporated — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2020. Insmed is a biopharmaceutical company whose commercial product is ARIKAYCE; its pipeline includes brensocatib and TPIP. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $43.6 million | $38.9 million | $123.0 million | $90.8 million |
| Gross profit / margin | $33.0 million / 75.7% | $32.4 million / 83.4% | $94.0 million / 76.4% | $75.3 million / 82.9% |
| Operating loss | $56.2 million | $56.5 million | $170.7 million | $188.2 million |
| Net loss | $63.7 million | $60.7 million | $191.9 million | $201.3 million |
| Net loss per share | $0.63 | $0.68 | $2.00 | $2.43 |
| Operating cash used | Not separately stated | Not separately stated | $152.6 million | $206.2 million |
- Q3 ARIKAYCE revenue grew 12.2% year over year; nine-month revenue grew 35.5%. U.S. sales were $42.0 million for Q3 and $118.2 million for nine months.
- Product cost rose faster than revenue: 65.0% in Q3 and 87.1% for nine months. Management attributed this partly to less sales of inventory whose costs had been expensed before FDA approval. Gross margin consequently fell year over year.
- Cash and cash equivalents were $588.8 million at September 30, up from $487.4 million at December 31, 2019. Working capital was $583.2 million. Nine-month investing cash outflow was $5.3 million; financing provided $259.0 million, including $245.9 million net proceeds from a second-quarter share offering.
- Debt consisted of $450 million principal of 1.75% convertible senior notes due 2025, carried at $351.1 million net of unamortized discount and issuance costs. The estimated fair value of the liability component was $505.5 million. The filing reports no principal repayments before 2025.
Changes versus comparable periods
- Nine-month revenue increased $32.2 million, while operating loss narrowed $17.5 million and net loss narrowed $9.5 million. The improvement in operating loss reflected revenue growth and lower SG&A, partly offset by higher product costs and R&D.
- Q3 net loss widened $3.0 million despite higher revenue and a slightly lower operating loss, largely alongside lower investment income and higher interest expense.
- R&D increased 20.6% in Q3 and 14.4% for nine months, reflecting clinical development, headcount and related costs. SG&A declined 12.7% in Q3 and 8.1% for nine months, principally because prior-year spending included a Cystic Fibrosis Foundation milestone; current-year commercial activities were also postponed.
Outlook, developments and risks
- Management said available funds were sufficient for at least the next 12 months, while warning that future cash needs would be substantial and additional capital may be needed. The company expected continued operating losses.
- Management expected product cost as a percentage of revenue to be higher in 2020 than in 2019, and R&D to increase with planned trials. A $12.5 million AstraZeneca contingent milestone was due upon first dosing in the Phase 3 brensocatib trial; management anticipated recognizing it in Q4 2020.
- Brensocatib’s Phase 2 WILLOW study met its primary endpoint at both doses; the 10 mg dose also reduced exacerbation rate significantly. The company planned to initiate the Phase 3 ASPEN trial by year-end 2020. These are clinical results, not approval or commercial guidance.
- ARIKAYCE received European Commission approval in October 2020, after quarter-end; management planned a Germany launch followed by the UK and other European markets, subject to reimbursement. A Japanese application was under review, with a potential launch in mid-2021 if approved. The FDA-required confirmatory ENCORE trial and ARISE patient-reported-outcome study were planned to start by year-end 2020.
- TPIP’s Phase 1 study began dosing in September; top-line data were expected in Q1 2021, with a Phase 2a PAH study planned for early 2021.
- COVID-19 had not materially affected results through September 30, but limited access to prescribers and could affect commercialization, trial enrollment and supply. No supply disruption had occurred; the company reported API sufficient for anticipated needs through 2022.
- ARIKAYCE customer concentration is significant: three customers accounted for 77% of gross product revenue for the nine months ended September 30, 2020. The company also relies on a limited number of contract manufacturers. Management did not expect ordinary-course legal proceedings to materially affect financial results.
Key facts for investors to verify
- Whether ARIKAYCE revenue growth, uptake and reimbursement support continued commercial expansion, especially amid COVID-related access limits.
- Whether gross margin improves or remains pressured as the mix of inventory costs changes.
- Timing, enrollment, results and regulatory implications of the ENCORE, ARISE, ASPEN and TPIP trials, and payment of the $12.5 million milestone.
- European reimbursement and launch progress, Japan’s regulatory decision, and the ability of manufacturing partners to support supply.
- Cash burn, financing needs, convertible-note terms and potential dilution; common shares outstanding rose to 101.8 million from 89.7 million at year-end 2019, primarily reflecting the share offering.